{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:57:12Z","timestamp":1788472632664,"version":"build-2803163510"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>The aims of this study were to investigate whether (early) PERCIST response monitoring with <jats:sup>18<\/jats:sup>F-FDG PET\/CT is predictive for progression-free survival (PFS) in unresectable stage III or IV melanoma patients treated with BRAF\/MEK inhibitor (MEKi) and to define dissemination patterns at progression with a lesion-based evaluation in direct comparison to baseline to improve our understanding of <jats:sup>18<\/jats:sup>F-FDG PET\/CT during BRAF\/MEKi.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>This prospective multicenter single-arm study included 70 patients with unresectable stage III\/IV <jats:italic toggle=\"yes\">BRAF<\/jats:italic>-mutated melanoma who underwent contrast-enhanced CT and <jats:sup>18<\/jats:sup>F-FDG PET\/CT at baseline and 2 and 7 weeks during treatment with vemurafenib plus cobimetinib and at progression if possible. Tumor response assessment was done with RECIST1.1 and PERCIST. Follow-up PET\/CT scans were visually compared with baseline to assess dissemination patterns.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Using RECIST1.1, PFS was not significantly different between the response groups (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.26). At 2 weeks, PERCIST median PFS was 15.7 months for patients with complete metabolic response (CMR) versus 8.3 months for non-CMR (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.035). The hazards ratio (HR) for progression\/death in non-CMR versus CMR was 1.99 (95% confidence interval [CI], 1.03\u20133.84; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.040) and 1.77 (95% CI, 0.91\u20133.43; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.0935) when adjusting for lactate dehydrogenase (LDH). At 7 weeks, median PFS for PERCIST CMR was 16.7 months versus 8.5 months for non-CMR (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.0003). The HR for progression\/death in the non-CMR group was significantly increased (HR, 2.94; 95% CI, 1.60\u20135.40; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.0005), even when adjusting for LDH (HR, 2.65; 95% CI, 1.43\u20134.91; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.0020). At week 7, <jats:sup>18<\/jats:sup>F-FDG PET\/CT was false-positive in all 4 (6%) patients with new FDG-avid lesions but CMR of known metastases. When <jats:sup>18<\/jats:sup>F-FDG PET\/CT was performed at progressive disease, 18\/22 (82%) patients had progression of known metastases with or without new <jats:sup>18<\/jats:sup>F-FDG\u2013avid lesions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study shows that PERCIST response assessment at week 7 is predictive for PFS, regardless of LDH. At 2 weeks, patients with CMR have longer PFS than patients with non-CMR, but different PET parameters should be investigated to further evaluate the added value of early <jats:sup>18<\/jats:sup>F-FDG PET\/CT. Disease progression on PET\/CT is predominated by progression of known metastases, and new <jats:sup>18<\/jats:sup>F-FDG\u2013avid lesions during BRAF\/MEKi are not automatically a sign of recurrent disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000004988","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T20:00:10Z","timestamp":1703016010000},"page":"138-145","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["The Predictive Value of FDG PET\/CT for Determining Progression-Free Survival in Advanced Stage III\u2013IV BRAF-Mutated Melanoma Patients Treated With Targeted Therapy\u2014What Can Be Learned From Progression?"],"prefix":"10.1097","volume":"49","author":[{"given":"Bernies","family":"van der Hiel","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Netherlands Cancer Institute\u2013Antoni van Leeuwenhoek"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Else A.","family":"Aalbersberg","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Netherlands Cancer Institute\u2013Antoni van Leeuwenhoek"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfons J.M.","family":"van den Eertwegh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Amsterdam UMC location Vrije Universiteit Amsterdam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda J.","family":"de Wit-van der Veen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Netherlands Cancer Institute\u2013Antoni van Leeuwenhoek"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel P.M.","family":"Stokkel","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Netherlands Cancer Institute\u2013Antoni van Leeuwenhoek"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Lopez-Yurda","sequence":"additional","affiliation":[{"name":"Department of Biometrics, Netherlands Cancer Institute\u2013Antoni van Leeuwenhoek"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Boellaard","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen W.","family":"Kapiteijn","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Leiden University Medical Center, Leiden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geke A.P.","family":"Hospers","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Center Groningen, Groningen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen J.B.","family":"Aarts","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, GROW-School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip Y.F.L.","family":"de Vos","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Center Utrecht, Utrecht"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marye J.","family":"Boers-Sonderen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Radboud University Medical Center, Nijmegen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid A.M.","family":"van der Veldt","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus Medical Center, Rotterdam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Willem B.","family":"de Groot","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Isala Oncology Center, Zwolle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.A.G","family":"Haanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","year":"2002","journal-title":"Nature"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3390\/cancers11081197","article-title":"Targeting oncogenic BRAF: past, present, and future","volume":"11","year":"2019","journal-title":"Cancers (Basel)"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2017.74.1025","article-title":"Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1001\/jamaoncol.2018.2668","article-title":"Modeled prognostic subgroups for survival and treatment outcomes in BRAF V600-mutated metastatic melanoma: pooled analysis of 4 randomized clinical trials","volume":"4","year":"2018","journal-title":"JAMA Oncol"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","year":"2019","journal-title":"N Engl J Med"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1200\/JCO.2011.39.1938","article-title":"Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma","volume":"30","year":"2012","journal-title":"J Clin Oncol"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"9006","DOI":"10.1200\/jco.2014.32.15_suppl.9006","article-title":"Metabolic tumor burden for prediction of overall survival following combined BRAF\/MEK inhibition in patients with advanced BRAF mutant melanoma","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ejca.2012.08.018","article-title":"(18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma","volume":"49","year":"2013","journal-title":"Eur J Cancer"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/MNM.0000000000000406","article-title":"Correlation between early 18F-FDG PET\/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma","volume":"37","year":"2016","journal-title":"Nucl Med Commun"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1007\/s00330-021-08355-1","article-title":"Prognostic value of total metabolic tumour volume and therapy-response assessment by [18F]FDG PET\/CT in patients with metastatic melanoma treated with BRAF\/MEK inhibitors","volume":"32","year":"2022","journal-title":"Eur Radiol"},{"issue":"Suppl 1","key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","year":"2009","journal-title":"J Nucl Med"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","article-title":"Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma","volume":"19","year":"2001","journal-title":"J Clin Oncol"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0002-9610(78)90171-X","article-title":"Metastatic pattern of malignant melanoma. A study of 216 autopsy cases","volume":"135","year":"1978","journal-title":"Am J Surg"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1038\/onc.2013.194","article-title":"Melanoma metastasis: new concepts and evolving paradigms","volume":"33","year":"2014","journal-title":"Oncogene"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11604-021-01174-w","article-title":"Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using (18)F-FDG PET\/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST","volume":"40","year":"2022","journal-title":"Jpn J Radiol"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2967\/jnumed.118.213652","article-title":"(18)F-FDG PET\/CT for monitoring of ipilimumab therapy in patients with metastatic melanoma","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1186\/s12885-017-3626-5","article-title":"Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study","volume":"17","year":"2017","journal-title":"BMC Cancer"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.2967\/jnumed.108.057182","article-title":"Standards for PET image acquisition and quantitative data analysis","volume":"50","year":"2009","journal-title":"J Nucl Med"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00259-009-1297-4","article-title":"FDG PET and PET\/CT: EANM procedure guidelines for tumour PET imaging: version 1.0","volume":"37","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00259-017-3740-2","article-title":"EANM\/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib25-20250621","article-title":"Software tools for standardized analysis of FDG whole body studies in multi-center trials","year":"2008","journal-title":"Soc Nuclear Med"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","year":"2009","journal-title":"Eur J Cancer"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1148\/radiol.2016142043","article-title":"Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0","volume":"280","year":"2016","journal-title":"Radiology"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1158\/1078-0432.CCR-11-2479","article-title":"Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma","volume":"18","year":"2012","journal-title":"Clin Cancer Res"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.immuni.2016.01.024","article-title":"MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade","volume":"44","year":"2016","journal-title":"Immunity"},{"issue":"Suppl 1","key":"bib30-20250621","first-page":"67","article-title":"The advantages and challenges of using FDG PET\/CT for response assessment in melanoma in the era of targeted agents and immunotherapy","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib31-20250621","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET study group","volume":"35","year":"1999","journal-title":"Eur J Cancer"},{"key":"bib32-20250621","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00259-017-3687-3","article-title":"Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib33-20250621","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s00259-017-3870-6","article-title":"Absolute number of new lesions on (18)F-FDG PET\/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab","volume":"45","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib34-20250621","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13550-019-0473-1","article-title":"Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST","volume":"9","year":"2019","journal-title":"EJNMMI Res"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004988","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:02:43Z","timestamp":1750532563000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004988","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,19]]}}}